Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 25, Number 11—November 2019

Synopsis

Vaccine-Derived Poliovirus Infection among Patients with Primary Immunodeficiency and Effect of Patient Screening on Disease Outcomes, Iran

Mohammadreza Shaghaghi1, Shohreh Shahmahmoodi1, Ali Nili, Hassan Abolhassani, Seyedeh Panid Madani, Ahmad Nejati, Maryam Yousefi, Yaghoob M. Kandelousi, Mona Irannejad, Shiva Shaghaghi, Seyed Mohsen Zahraei, Sussan Mahmoudi, Mohammad Mehdi Gouya, Reza Yazdani, Gholamreza Azizi, Nima Parvaneh, and Asghar AghamohammadiComments to Author 
Author affiliations: Johns Hopkins Hospital, Baltimore, Maryland, USA (M. Shaghaghi); Tehran University of Medical Sciences, Tehran, Iran (M. Shaghaghi, S. Shahmahmoodi, A. Nili, H. Abolhassani, S.P. Madani, A. Nejati, M. Yousefi, Y.M. Kandelousi, M. Irannejad, S. Shaghaghi, R. Yazdani, N. Parvaneh, A. Aghamohammadi); Research Center for Immunodeficiencies, Tehran (M. Shaghaghi, A. Nili, H. Abolhassani, S.P. Madani, M. Irannejad, S. Shaghaghi, R. Yazdani, N. Parvaneh, A. Aghamohammadi); Karolinska University Hospital Huddinge, Stockholm, Sweden (H. Abolhassani); Ministry of Health and Medical Education, Tehran (S.M. Zahraei, S. Mahmoudi, M.M. Gouya); Alborz University of Medical Sciences, Karaj, Iran (G. Azizi); Non-Communicable Diseases Research Center, Karaj (G. Azizi)

Main Article

Figure 2

Timeline of Iran’s registry of iVDPV infection, showing the number of patients identified after acute flaccid paralysis or through screening, 1995–2018. The iVDPV detection rate was initially accelerated after implementation of the poliovirus screening program. The switch in vaccination schedule from trivalent to bivalent oral poliovirus vaccine was applied in 2016, leading to a decrease in iVDPV serotype 3 emergence. Two patients excreted iVDPVs with combined serotypes 1 and 2. One patient excr

Figure 2. Timeline of Iran’s registry of iVDPV infection, showing the number of patients identified after acute flaccid paralysis or through screening, 1995–2018. The iVDPV detection rate was initially accelerated after implementation of the poliovirus screening program. The switch in vaccination schedule from trivalent to bivalent oral poliovirus vaccine was applied in 2016, leading to a decrease in iVDPV serotype 3 emergence. Two patients excreted iVDPVs with combined serotypes 1 and 2. One patient excreted 2 distinct iVDPVs (serotypes 2 and 3). Numbers in each square indicate the iVDPV serotype. iVDPV, immunodeficiency-associated vaccine-derived poliovirus; OPV, oral poliovirus vaccine.

Main Article

1These first authors contributed equally to this article.

Page created: October 15, 2019
Page updated: October 15, 2019
Page reviewed: October 15, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external